2-(Hydroxyimino)-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide | 92952-47-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-(Hydroxyimino)-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
• 英文别名: 2-hydroxyimino-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
• CAS: 92952-47-1
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: IUSUPBSIPPMFKR-UHFFFAOYSA-N

物化性质

• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(Hydroxyimino)-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 生成 6,7,8,9-四氢-1H-苯并[g]吲哚-2,3-二酮
  参考文献：
  名称：

  Methods and compositions for selectin inhibition

  摘要：

  本发明涉及抗炎物质领域，更特别地涉及新型化合物，其作为哺乳动物粘附蛋白选择素的拮抗剂。在某些实施例中，提供了治疗选择素介导的疾病的方法，其中包括给予式I化合物的给药，其中组成变量在此处定义。

  公开号：

  US20050101569A1
• 作为产物：
  描述：

  1-氨基四氢化萘 生成 2-(Hydroxyimino)-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
  参考文献：
  名称：

  Methods and compositions for selectin inhibition

  摘要：

  本发明涉及抗炎物质领域，更特别地涉及新型化合物，其作为哺乳动物粘附蛋白选择素的拮抗剂。在某些实施例中，提供了治疗选择素介导的疾病的方法，其中包括给予式I化合物的给药，其中组成变量在此处定义。

  公开号：

  US20050101569A1

文献信息

• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20080255192A1

  公开（公告）日：2008-10-16

  The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。
• Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands
  申请人：Roffey Richard Anthony Jonathan

  公开号：US20050187282A1

  公开（公告）日：2005-08-25

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式（I）的化合物，其中R1和R2分别选自氢和烷基；R3是烷基；R4和R5选自氢和烷基；R6和R7分别选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷基硫基、烷基亚砜基、硝基、氰基、羧酸酯基、羧酸芳酯基和羧基；A是一个含有一个或多个杂原子的5-或6元环，其中环A的原子除了与环A融合的苯环的不饱和碳原子外，可以是饱和的或不饱和的，以及其药学上可接受的盐、加合物和前药；以及其在治疗中的用途，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如在治疗中枢神经系统疾病；中枢神经系统损伤；心血管疾病；胃肠道疾病；尿崩症和睡眠呼吸暂停症，特别是用于肥胖症的治疗。
• Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
  申请人：Roffey Richard Anthony Jonathan

  公开号：US20050192334A1

  公开（公告）日：2005-09-01

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式为（I）的化合物，其中R1和R2独立地选自氢和烷基；R3为烷基；R4和R5选自氢和烷基；R6和R7独立地选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷硫基、烷基亚砜基、硝基、氰基、羧基酯基、芳羧基酯基和羧基；A是一个5-或6-成员环，可选地含有一个或多个杂原子，其中环A的原子除与环A融合的苯环的不饱和碳原子外，均为饱和或不饱和的，以及其药学上可接受的盐、加合物和前药；以及其在治疗中的使用，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如在中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症和睡眠呼吸暂停症的治疗中，特别是用于肥胖症的治疗。
• Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands
  申请人：Roffey Anthony Jonathan Richard

  公开号：US20070105889A1

  公开（公告）日：2007-05-10

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式为（I）的化合物，其中R1和R2分别选自氢和烷基；R3为烷基；R4和R5选自氢和烷基；R6和R7分别选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷硫基、烷基亚砜基、硝基、氰基、羧甲氧基、羧芳氧基和羧基；A是一个5或6元环，可以包含一个或多个杂原子，环A的原子，除了与环A融合的苯环的不饱和碳原子外，都是饱和或不饱和的，并且其药物可接受的盐、加成物和前药；以及其在治疗中的应用，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如在中枢神经系统疾病的治疗中；中枢神经系统损伤；心血管疾病；胃肠道疾病；尿崩症和睡眠呼吸暂停症，特别是用于肥胖症的治疗。
• Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands
  申请人：Roffey Jonathan Richard Anthony

  公开号：US20080125455A1

  公开（公告）日：2008-05-29

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system, cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式为（I）的化合物，其中R1和R2独立地选自氢和烷基；R3是烷基；R4和R5选自氢和烷基；R6和R7独立地选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷硫基、烷基亚砜基、硝基、氰基、羧甲氧基、羧芳氧基和羧基；A是一个5或6成员环，可选地含有一个或多个杂原子，其中环A的原子，除了与环A融合的苯环的不饱和碳原子外，均为饱和或不饱和的，并且其药学上可接受的盐、加合物和前药；以及在治疗中的使用，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如用于治疗中枢神经系统疾病；中枢神经系统损伤、心血管疾病；胃肠道疾病；尿崩症和睡眠呼吸暂停症，特别是用于治疗肥胖症。